Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebronucimab PK similarity in healthy Chinese males
NCT07043283Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Oct 2025
- Primary completion
- Feb 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ebronucimab in hypercholesterolemia (2 arms), sponsored by Akeso, Inc. Primary endpoints: Maximum plasma concentration and Area under curve. Started Oct 2025; status: completed.
02
Drugs
ebronucimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07043283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043283.